Viewing data from:

POLYETHYLENE GLYCOL 3350

ANDA

POLYETHYLENE GLYCOL 3350 | A202850 | ANI PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 5 NDCs

Highest NADAC/Unit

$1.24

per ea

Lowest NADAC/Unit

$1.24

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
62559015710POLYETHYLENE GLYCOL 3350 POWD	$1.24	EA	Generic	—	2026-10-21
62559015730POLYETHYLENE GLYCOL 3350 POWD	$1.24	EA	Generic	—	2026-10-21
72603030202POLYETHYLENE GLYCOL 3350 POWD	$1.24	EA	Generic	—	2026-10-21
72603030203POLYETHYLENE GLYCOL 3350 POWD	$1.24	EA	Generic	—	2026-10-21
72603030204POLYETHYLENE GLYCOL 3350 POWD	$1.24	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$19.24

Highest Price

$73.37

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
62559-0157-10POLYETHYLENE GLYCOL 3350 17GM/PKT PWDR,ORAL	$73.37	FSS	Golden State Medical Supply, Inc.	06/14/2028
62559-0157-30POLYETHYLENE GLYCOL 3350 17GM/PKT PWDR,ORAL	$19.24	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain4 active DMFs

4 active API suppliers hold Drug Master Files for this ingredient.

BASF CORPPOLYETHYLENE GLYCOL 3350

DMF 169462003

AVESTA PHARMA PVT LTDPOLYETHYLENE GLYCOL 3350 USP

DMF 274192013

CLARIANT CHEMICALS (HUIZHOU) LTDPOLYETHYLENE GLYCOL 3350 USP/NF

DMF 323552018

PHARCOS SPECIALITY LTDPOLYETHYLENE GLYCOL 3350 USP

DMF 413202025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 17GM/SCOOPFUL

0 patents0 exclusivities▴

FOR SOLUTION;ORAL | Approved: Dec 15, 2015

No patent or exclusivity listings for this strength.

#002 — 17GM/PACKET

0 patents0 exclusivities▾

FOR SOLUTION;ORAL | Approved: Nov 30, 2021